Antiplatelet Effect of Aspirin in Patients with Cerebrovascular Disease

Stroke

Volumn 35, Issue 1, 2004, Pages 175-178

  Alberts, Mark J ^a   Bergman, Deborah L ^b   Molner, Elise ^c   Jovanovic, Borko D ^a   Ushiwata, Issei ^d   Teruya, Jun ^e,f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d San ai Hospital   (Japan)

^e TEXAS CHILDREN S HOSPITAL   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiplatelet therapy; Aspirin; Cerebrovascular disorders; Stroke, ischemic

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DEMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; ENTERIC COATED TABLET; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

AGE FACTORS; ASPIRIN; BLOOD PLATELETS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; INPATIENTS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; ODDS RATIO; OUTPATIENTS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED;

EID: 0346726095     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000106763.46123.F6     Document Type: Article

References (23)

1. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415-521.
2. Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988;19: 547-554.
3. Grau A, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German Stroke Data Bank. Stroke. 2001;32:2559-2566.
4. The Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA. 1998;279:1265-1272.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
6. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655. Comment.
7. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
8. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331-2336.
9. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD. Aspirin response and failure in cerebral infarction. Stroke. 1993;24:345-350.
10. Mammen E, Comp P, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24: 195-202.
11. Rand M, Carcao M, Blanchette V. Use of the PFA-100 in the assessment of primary platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost. 1998;24:523-529.
12. Carcao M, Blanchette V, Dean J, Kern M, Stain A, Sparling C, Stephens D, Ryan GJ, Freedman J, Rand M. The platelet function analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Hematol. 1998;101:70-73.
13. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1996; 60:197-199.
14. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets. 2002; 13:37-40.
15. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
16. Grau A, Reiners S, Med C, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke. Stroke. 2003; 34:849-855.
17. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;66:255. Letter.
18. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23:349-356.
19. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001;110:28S-32S.
20. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, Weissmann G. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A. 1998;95:14540-14545.
21. Feldman M, Jialal I, Devarag S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol. 2001;37:2036-2041.
22. Hart R, Leonard A, Talbert R, Pearce L, Cornell E, Bovill E, Feinberg W. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy. 2003;23:579-584.
23. Gum P, Kotke-Marchant K, Welsh P, White J, Topol E. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965.